Department of Chemistry, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia.
Department of Chemistry, Faculty of Education, University of Dalanj, Dalanj, Sudan.
Luminescence. 2024 Jan;39(1):e4672. doi: 10.1002/bio.4672.
The reaction of 4-(chloroacetamido)pyrimidine (1) with ammonium thiocyanate gave 2-(pyrimidin-4-ylimino)thiazolidin-4-one (2), which, when condensed with four substituted benzaldehyde analogues, gave the consequent 5-arylidine-2-(pyrimidin-4-ylimino)thiazolidin-4-ones 3a-d. In addition, the absorbance and fluorescence behaviours of pyrimidinylimino-thiazolidin-4-one hybrids 3a-d in various organic solvents were investigated. The emphasis was on studying UV absorption capacities and the effect of various structural components on photophysical qualities such as the 5-arylidene-2-(pyrimidin-4-ylimino)thiazolidin-4-ones and N,N-dimethylamino tail. The cytotoxic effect of four pyrimidinylimino-thiazolidin-4-one hybrids 3a-d on tumour cell lines (HepG2, HCT-116, PC3, MCF-7) and a normal cell line (WI38) is investigated in this work. The cytotoxicity was measured by comparing the half-maximal inhibitory concentration (IC ) to the reference medication, 5-fluorouracil. The findings indicate that these hybrid compounds had varying cytotoxic effects on the cell lines examined; hybrids 3b and 3c demonstrated significant anticancer activity against MCF-7 with IC values of 7.53 ± 0.43 and 9.17 ± 0.31 μM, respectively. The inhibitory efficacy of various synthesized hybrids on the epidermal growth factor receptor (EGFR) kinase was investigated. EGFR is a crucial target in cancer treatment because inhibiting it may reduce tumour development and proliferation. The IC value was used to calculate the inhibitory activity, which is the concentration of inhibitor necessary to induce half-maximal inhibition of EGFR kinase activity. In addition, the predicted ADME results show that pyrimidinylimino-thiazolidin-4-one hybrids have good pharmacokinetic properties; hybrid 3d is more lipophilic than the other compounds. It has a medium molecular weight, a small number of hydrogen bond acceptors and donors, and a large number of aromatic heavy atoms. Moreover, molecular docking simulations revealed precise information on the interactions of pyrimidinylimino-thiazolidin-4-one hybrids 3a-d and 5-Fu with their respective protein targets. These interactions point to possible pathways for their biological activities and call for more testing to establish their effectiveness as bioactive molecules or therapeutic candidates.
4-(氯乙酰胺基)嘧啶(1)与硫氰酸铵反应生成 2-(嘧啶-4-基亚氨基)噻唑烷-4-酮(2),当与四个取代苯甲醛类似物缩合时,得到相应的 5-亚芳基-2-(嘧啶-4-基亚氨基)噻唑烷-4-酮 3a-d。此外,还研究了嘧啶基亚氨基-噻唑烷-4-酮杂合体 3a-d 在各种有机溶剂中的吸收和荧光行为。重点研究了 UV 吸收能力以及各种结构成分对光物理性质的影响,如 5-亚芳基-2-(嘧啶-4-基亚氨基)噻唑烷-4-酮和 N,N-二甲基氨基尾部。本文研究了四种嘧啶基亚氨基-噻唑烷-4-酮杂合体 3a-d 对肿瘤细胞系(HepG2、HCT-116、PC3、MCF-7)和正常细胞系(WI38)的细胞毒性。通过比较半最大抑制浓度(IC)与参考药物 5-氟尿嘧啶,来测量细胞毒性。结果表明,这些杂合体化合物对所检查的细胞系表现出不同的细胞毒性作用;杂合体 3b 和 3c 对 MCF-7 表现出显著的抗癌活性,IC 值分别为 7.53±0.43 和 9.17±0.31μM。还研究了各种合成杂合体对表皮生长因子受体(EGFR)激酶的抑制作用。EGFR 是癌症治疗的重要靶点,因为抑制它可以减少肿瘤的发展和增殖。IC 值用于计算抑制活性,即诱导 EGFR 激酶活性半最大抑制所需的抑制剂浓度。此外,预测的 ADME 结果表明,嘧啶基亚氨基-噻唑烷-4-酮杂合体具有良好的药代动力学性质;杂合体 3d 比其他化合物更亲脂。它具有中等分子量、较少的氢键供体和受体以及较多的芳香重原子。此外,分子对接模拟揭示了嘧啶基亚氨基-噻唑烷-4-酮杂合体 3a-d 和 5-Fu 与各自蛋白靶标的相互作用的精确信息。这些相互作用表明了它们生物活性的可能途径,并呼吁进行更多的测试以确定它们作为生物活性分子或治疗候选物的有效性。